• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Amgen 2018 Layoffs









It was a good ride until it lasted - we officially were toast in the middle of March with Outcomes data at ACC. Managed care is adding Praluent as preferred left and right with major price break . I guess we can pray for another patent infringement appeal. We're screwed!!!
 












Well folks, I think the next 6 mos or so will really tell the tale. If Repatha loses anymore access with these big PBMs it is done. We had a disadvantage in coverage before the ES news. Yikes. Amgen market access team not doing the field any favors.
 




Well folks, I think the next 6 mos or so will really tell the tale. If Repatha loses anymore access with these big PBMs it is done. We had a disadvantage in coverage before the ES news. Yikes. Amgen market access team not doing the field any favors.

The OCT team only works on Oct 15th and is more secretive than the CIA.
 




Well folks, I think the next 6 mos or so will really tell the tale. If Repatha loses anymore access with these big PBMs it is done. We had a disadvantage in coverage before the ES news. Yikes. Amgen market access team not doing the field any favors.

If you were good at selling Repatha and built more demand, maybe the RAS’s could get more business!